Recruiting studies: Ribociclib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Out
NA · 4 location(s) · Dosentrx Ltd. · NCT06344416 A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in
Phase N/A · 284 location(s) · Novartis Pharmaceuticals · NCT06830720 Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Recepto
Phase N/A · 40 location(s) · Novartis Pharmaceuticals · NCT06930859 Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Nagoya City University · NCT07164976 Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management
NA · 3 location(s) · Institut fuer Frauengesundheit · NCT07708571 Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
Phase 3 · 203 location(s) · Celcuity Inc · NCT06757634 A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
Phase 2 · 2 location(s) · National Taiwan University Hospital · NCT05766410 Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Phase 3 · 229 location(s) · Novartis Pharmaceuticals · NCT05827081 Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07243002 Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2-
Phase 1 · 3 location(s) · University of Michigan Rogel Cancer Center · NCT05996107 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic
Phase 3 · 72 location(s) · National Cancer Institute (NCI) · NCT07391774 To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
Phase N/A · 1 location(s) · Fondazione Sandro Pitigliani · NCT04660435 Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive
Phase 2 · 21 location(s) · Oana Danciu · NCT05467891 First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139 Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NA · 39 location(s) · Natera, Inc. · NCT07214532 A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R
Phase 2 · 49 location(s) · Hoffmann-La Roche · NCT07405801 Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Recep
Phase 2 · 2 location(s) · Korea University Guro Hospital · NCT05816655 Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrin
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06656624 Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemo
Phase 3 · 4 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07400523 Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and W
Phase N/A · 7 location(s) · Novartis Pharmaceuticals · NCT06905301 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3 · 74 location(s) · BeOne Medicines · NCT07492641 Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3 · 167 location(s) · Olema Pharmaceuticals, Inc. · NCT07085767 Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer
Phase 2 · 16 location(s) · MedSIR · NCT07195227 RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast
Phase N/A · 2 location(s) · Novartis Pharmaceuticals · NCT06797531 Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
Phase N/A · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06587789 Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+,
Phase 1 · 16 location(s) · Olema Pharmaceuticals, Inc. · NCT05508906 A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Phase 3 · 84 location(s) · AstraZeneca · NCT07647328 Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 · 20 location(s) · Nationwide Children's Hospital · NCT05843253 Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Ot
Phase 1/Phase 2 · 33 location(s) · Novartis Pharmaceuticals · NCT06726148 Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Phase 2 · 7 location(s) · Karolinska University Hospital · NCT05900206

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.